Former Symphogen colleagues reunited in Norwegian biotech company
Former CEO of Symphogen Martin Olin, who has spearheaded Norwegian biotech company Bergenbio since September last year, can now greet a past colleague from Symphogen as Anders Tullgren steps in to chair Bergenbio.
by ALBERT RØNNING-ANDERSSON, translated by daniel pedersen
CEO of Norwegian biotech company Bergenbio Martin Olin, who for a short time was a managing partner in venture capital firm Nordic Eye, will now be joined by a former colleague from his days at Symphogen, where Olin was in charge until October 2020 – few months after the company was sold for an estimated DKK 3bn (USD 455.7m) to French Servier.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
